European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.
about
Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactionsOral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 studyPhase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia.Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.The role of clofarabine in acute myeloid leukemia.SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia.Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.Dose escalation of lenalidomide in relapsed or refractory acute leukemias.Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia.Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemiaA multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapyVosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.Synergism between clofarabine and decitabine through p53R2: a pharmacodynamic drug-drug interaction modeling.Clofarabine in the treatment of acute myeloid leukemia in older adultsClofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemiaAcute myeloid leukaemia: optimal management and recent developments.Treatment of acute myeloid leukemia with 20-30% bone marrow blasts.Genetic and epigenetic variants contributing to clofarabine cytotoxicity.Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.Older patients with acute myeloid leukemia.Acute myeloid leukaemia in the elderly: a review.Unfavorable-risk cytogenetics in acute myeloid leukemia.Clofarabine for myelodysplastic syndromes.Upfront therapy of acute myeloid leukemia.How to manage high-risk acute myeloid leukemia.Clofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adults.Clofarabine in pediatric acute leukemia: current findings and issues.Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?Novel and emerging drugs for acute myeloid leukemiaEfficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial.Acute myeloid leukemia: focus on novel therapeutic strategies.Late-phase investigational approaches for the treatment of relapsed/refractory acute myeloid leukemia.Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century.Clofarabine-induced kidney toxicity.
P2860
Q27851694-7A863DEB-A5A1-4243-9F42-D1B6753BB55CQ28535342-DE40D4B7-3057-470E-B007-37769ABEC813Q33403865-EA9245BC-B467-41A1-BD4B-B561260D84D9Q33412609-BF655EBA-4A71-406E-A6B8-567F1AAA75B7Q33903024-5491EF9F-A202-4DF4-ADDB-5AC411F70377Q34106830-C66C9E0C-7B59-4955-9078-18FD7277AD0EQ34267853-8C1824C0-1F08-4519-990C-54022CD1D8F4Q34298181-BD87A68F-032B-40BC-9CAE-6B6D774BA227Q34302258-F1AF54F5-BBDC-4CB4-9718-B4AE6FC36AA5Q34465347-FDA1BB9E-E9B6-442D-8939-62E2FA3CF742Q34488712-D43DA96F-DF27-4CFD-951B-A6F46A02DA59Q35278018-2AE83D55-DDCF-400C-9EAC-44DE0B275167Q35584427-65D9ECEB-781A-47F8-9724-D30173C6D892Q35651754-63D26121-5947-4E31-9736-011CD8DFC37CQ35794439-1F0A6424-B89D-4A46-A299-F2932C78179FQ35954771-28592068-B159-4B14-A3C7-7C38E609D9E5Q36275976-28FF817F-A570-40E0-A7CE-F93E8F59BA8EQ36776439-ACF35146-2E54-4719-96C9-97E9CA422EA8Q36806921-84358407-9761-4595-BE42-2BBBE2C7E81AQ36914091-4CB63D0D-5B0C-4ED2-B101-6F45955232E2Q36934199-859AA930-470C-4B84-AF55-46852308E92EQ37153800-5EB25B2C-B8FE-4416-96F2-C46DD84188A9Q37533323-06E3FF28-72CF-4877-B295-D7C6699E904FQ37625632-1269E1C3-8CCD-4613-BD0C-E4AA35C2D8B6Q37810969-F79455F9-20B9-4642-8D34-B168F2AA20BDQ37840260-A4A787B9-1B72-463E-A3AD-D737C67D340DQ37865545-BBCFF69D-2FA8-4502-A49A-00A467FCB684Q37876909-AD67A665-C793-4F78-A3CA-EABA7CAA3651Q37897183-E1D930A1-7724-428E-B865-32577A8F9292Q37960820-5F18EE58-D5AA-46A7-8999-324D96A8C488Q37968584-7FBB0D90-BB67-49E1-A7AE-50F9A80E0483Q37987061-B78990A8-2CFE-4F09-A362-277E6F7AECBCQ37994256-6BBC0105-6012-47DB-A518-2BCF2A29EAFAQ38000711-D823852C-EE36-4F6E-90E1-AFFCA255832DQ38003665-53F0B15F-1604-48A2-B592-7ADF15314DFEQ38015336-60204C7C-F013-420D-9473-FD673A0BE105Q38042705-ADFEE7DB-DD06-4628-BEB9-62B73A39695DQ38091393-BFB1E26E-5B9F-49A9-B0C7-6B8A18720B0EQ38104287-773C99C6-DCD0-4169-A94F-CB323499C125Q38147971-7B72C6A5-137D-4573-AB65-53498E90685F
P2860
European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
European development of clofar ...... le for intensive chemotherapy.
@en
European development of clofar ...... le for intensive chemotherapy.
@nl
type
label
European development of clofar ...... le for intensive chemotherapy.
@en
European development of clofar ...... le for intensive chemotherapy.
@nl
prefLabel
European development of clofar ...... le for intensive chemotherapy.
@en
European development of clofar ...... le for intensive chemotherapy.
@nl
P2093
P356
P1476
European development of clofar ...... le for intensive chemotherapy.
@en
P2093
Alan K Burnett
Ann Hunter
Dominic Culligan
Donald Milligan
Emma Das-Gupta
John Murphy
Jonathan Kell
Mary-Frances McMullin
Michael Dennis
P304
P356
10.1200/JCO.2009.26.4242
P407
P577
2010-04-12T00:00:00Z